
Annual report 2025
added 04-11-2026
PainReform Ltd. EPS Ratio 2011-2026 | PRFX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.47 | -32.2 | -63.1 | -63.5 | -7.25 | -1.25 | -4.17 | -3.24 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.25 | -63.5 | -22.8 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.97 | 6.43 % | $ 9.55 B | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 5.12 | 11.55 % | $ 345 B | ||
|
Aligos Therapeutics
ALGS
|
-2.45 | $ 7.66 | 3.23 % | $ 75.7 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 320.13 | -3.98 % | $ 41.9 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.81 | 0.6 % | $ 1.02 B | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 4.67 | -1.37 % | $ 766 M | ||
|
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 102.12 | 2.66 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 3.08 | -4.94 % | $ 5.07 M | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.35 | -12.9 % | $ 347 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.26 | 0.47 % | $ 456 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 24.19 | -1.59 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.61 | 8.05 % | $ 428 M | ||
|
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-26.8 | - | - | $ 1.41 B | ||
|
BioXcel Therapeutics
BTAI
|
-5.73 | $ 1.07 | 1.9 % | $ 13.1 M | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 3.52 | 3.53 % | $ 354 M | ||
|
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
ChromaDex Corporation
CDXC
|
0.22 | - | -0.88 % | $ 598 M |